Training activity information
Details
Analyse, interpret and draft a clinical report for the genetic analysis for the identification of sequence variants within the ABL1 tyrosine kinase domains for patients with sub-optimal response to CML treatment
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Considerations
Principles of the molecular testing strategy and process IQC and EQA Best practice guidelines for reporting, including recommendations for patient treatment and management, follow up, further testing or clinical trials, if relevant Correct scientific and clinical terminology, including HGVS nomenclature Communication of complex scientific information to the multidisciplinary team
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What knowledge do you have regarding the ABL1 tyrosine kinase domain and common sequence variants associated with drug resistance in CML?
- Are you familiar with the laboratory molecular assays used for identifying these variants?
- What are the key elements required in a clinical report to effectively communicate these findings to clinicians?
- What specific insights do you hope to gain into the interpretation of ABL1 sequence variant data in the context of CML treatment resistance?
- How will this activity enhance your skills in analysing complex molecular data and translating it into a clinically relevant report?
- Consider possible challenges you might face during the analysis and interpretation and think about how you might handle them.
- Review relevant protocols and guidelines for ABL1 mutation testing and reporting.
In action
- What actions are you taking as you analyse the genetic data for ABL1 tyrosine kinase domain variants? Why are you approaching the analysis in this specific way?
- What decisions are you making about which data points to prioritise or how to interpret specific findings? What is informing these decisions?
- How effective do you feel your actions are in identifying relevant sequence variants? Are you encountering any challenges in the process, such as ambiguous data or complex reports?
- What can you learn about the process of ABL1 kinase domain mutation analysis as it unfolds? Are there any patterns or unexpected results emerging that are informing your understanding?
- How are you adapting to any challenges or uncertainties that arise during the analysis? Are you considering alternative approaches to interpretation or seeking clarification on specific points?
On action
- What did you notice during the process of analysing the genetic data for ABL1 tyrosine kinase domain variants in patients with sub-optimal response to Chronic Myeloid Leukaemia (CML) treatment? Consider the specific data points, any challenges in interpretation, and the overall workflow.
- What did you learn from this activity about the genetic mechanisms of resistance to CML treatment? What specific knowledge or skills did you develop or improve in relation to analysing ABL1 kinase domain mutations?
- What will you take from this experience moving forward in terms of your approach to analysing and reporting on drug resistance mutations in haematological malignancies? What areas for continued development have been identified as a result of this activity, such as specific bioinformatics tools, interpretation guidelines, or reporting standards? What actions will you now take to develop your practice in this area?
Beyond action
- Have subsequent cases or learning about mechanisms of resistance in CML provided new insights into your previous interpretations?
- Have discussions about challenging CML cases with ABL1 kinase domain mutations provided new perspectives or learning points?
- How have subsequent experiences enhanced your understanding of the role of molecular diagnostics in guiding treatment decisions for CML?
- Have you been more attentive to specific ABL1 mutations or their reported clinical significance in subsequent case analyses or discussions?
- How will you stay updated on the evolving knowledge of resistance mechanisms and the role of ABL1 kinase domain mutation testing in CML?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 4 |
Outcome
Analyse, interpret and prepare interpretive reports for common haematological malignancies, including results for somatic variants, kinase domain mutations, measurable residual disease and post-transplant monitoring. |
| # 5 |
Outcome
Interpret the associated IQC and EQA of the laboratory tests for investigation of haematological malignancies. |
| # 6 |
Outcome
Practice with the relevant specialities for the diagnosis, monitoring and management of haematological malignancies. |